Intraventricular Nimodipine Reduces Delayed Cerebral Ischemia after aSAH
This study is a randomized, phase 1/2a, dose-escalation trial to investigate the safety and efficacy of intraventricular sustained-release nimodipine (EG-1962) in aneurysmal subarachnoid hemorrhage. The authors showed that EG-1962 is safe at 800 mg and is associated with reduced delayed cerebral ischemia and better outcome than conventional enteral nimodipine.
The NEWTON (Nimodipine Microparticles to Enhance Recovery While Reducing Toxicity After Subarachnoid Hemorrhage) investigators enrolled 72 patients in the study, 54 randomized to EG-1962 group and 18 to enteral group. Favorable outcome (extended Glasgow outcome score 6-8) at 90 days occurred in 27/45 (60%) EG-1962 subjects and 5/18 (28%) enteral subjects (p=0.027). There was no EG-1962 related hypotension and 1 transient allergic reaction. These promising results have led to the start of a phase 3 randomized clinical study of EG-1962 compared with enteral nimodipine.